{"id":"NCT02974907","sponsor":"ReGenTree, LLC","briefTitle":"Assessment of the Safety and Efficacy of RGN-259 Ophthalmic Solutions for Dry Eye Syndrome : ARISE-2","officialTitle":"A Multi-Center, Randomized, Double Masked, Placebo Controlled Clinical Study to Assess the Safety and Efficacy of RGN-259 Ophthalmic Solutions for the Treatment of Dry Eye : ARISE-2","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-11","primaryCompletion":"2017-09","completion":"2018-03","firstPosted":"2016-11-29","resultsPosted":"2022-01-05","lastUpdate":"2022-01-05"},"enrollment":601,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Dry Eye Syndrome"],"interventions":[{"type":"DRUG","name":"RGN-259","otherNames":["TÎ²4","Thymosin Beta 4"]},{"type":"DRUG","name":"Placebo","otherNames":["Vehicle Control"]}],"arms":[{"label":"RGN-259","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objective of this study is to compare the safety and efficacy of RGN-259 Ophthalmic Solutions to placebo for the treatment of the signs and symptoms of dry eye.","primaryOutcome":{"measure":"Ocular Discomfort","timeFrame":"29 days after first dosing","effectByArm":[{"arm":"RGN-259","deltaMin":0.07,"sd":null},{"arm":"Placebo","deltaMin":-0.04,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":3},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":299},"commonTop":["Nasopharyngitis","Visual Acuity Reduced","Sinusitis","Eye Pain","Upper Respiratory Tract Infection"]}}